Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8192267 | 0.83 | ENPP3 (0.42) | MAPK13MAPK12MAPK11MAPK14PTGS2 | |
| SCHEMBL2091239 | 0.81 | MAPK13 (0.83) | MAPK13MAPK12MAPK11MAPK14PTGS2 | |
| SCHEMBL869242 | 0.81 | GAA (0.51) | MAPK13MAPK12MAPK11MAPK14GAA | |
| SCHEMBL7948113 | 0.80 | RAB9A (0.47) | MAPK13MAPK12MAPK11MAPK14KMT2A | |
| SCHEMBL9434736 | 0.79 | NPC1 (0.39) | MAPK13MAPK12MAPK11MAPK14PTGS2 | |
| SCHEMBL21051602 | 0.79 | NPC1 (0.40) | MAPK13MAPK12MAPK11MAPK14PTGS2 | |
| SCHEMBL5546174 | 0.79 | CCR9 (0.44) | MAPK13MAPK12MAPK11MAPK14PTGS2 | |
| SCHEMBL5318103 | 0.79 | NR4A2 (0.63) | MAPK13MAPK12MAPK11MAPK14PTGS2 | |
| SCHEMBL272772 | 0.79 | NPC1 (0.50) | MAPK13MAPK12MAPK11MAPK14GAA | |
| SCHEMBL1617773 | 0.79 | ACHE (0.43) | MAPK13MAPK12MAPK11MAPK14PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170369483-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| EP-1798223-B2 | Aryl sulfonamides | CHEMOCENTRYX INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8211896-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| EP-1562940-A2 | ARYL SULFONAMIDES | ChemoCentryx Inc (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050165067-A1 | Aryl sulfonamides | CHEMOCENTRYX | 2005-07-28 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20050137193-A1 | Aryl sulfonamides | CHEMOCENTREYX | 2005-06-23 | — | — | US | disclosed |
| US-20040171654-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004046092-A2 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-06-03 | — | — | WO | disclosed |
| US-5041567-A | Human and veterianary medicine; veneral diseases respiratory diseases, bovine mastitis | BEECHAM GROUP PLC (GB) | 1991-08-20 | — | — | US | disclosed |
| US-4812470-A | Antibacterial monic acid derivatives | BEECHAM GROUP P.L.C. (GB) | 1989-03-14 | — | — | US | disclosed |
| EP-0087953-B1 | ANTIBACTERIAL 1-NORMON-2-YL-HETEROCYCLIC COMPOUNDS | BEECHAM GROUP PLC (GB) | 1988-04-27 | — | — | EP | disclosed |
| EP-0087953-A2 | Antibacterial 1-normon-2-yl-heterocyclic compounds | BEECHAM GROUP PLC (GB) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137193-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | MAPK13 1998/4885MAPK12 1468/4885MAPK11 1642/4885 |
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | MAPK13 1998/4885MAPK12 1468/4885MAPK11 1642/4885 |
| US-20120014997-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | MAPK13 1998/4885MAPK12 1468/4885MAPK11 1642/4885 |
| US-20170369483-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | MAPK13 1998/4885MAPK12 1468/4885MAPK11 1642/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | MAPK13 1998/4885MAPK12 1468/4885MAPK11 1642/4885 |
| US-20040171654-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | MAPK13 1998/4885MAPK12 1468/4885MAPK11 1642/4885 |
| US-20050165067-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | MAPK13 1998/4885MAPK12 1468/4885MAPK11 1642/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | MAPK13 1998/4885MAPK12 1468/4885MAPK11 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.